Healthcare Providers and Services
Company Overview of Mount Sinai Hospital
Mount Sinai Hospital operates pre-eminent patient care, and research and academic health science centers. The company provides treatments in the areas of surgical oncology; fertility, pre-natal, and mother and baby care; emergency medicine and critical care; chronic diseases, such as arthritis, diabetes, heart failure, or GI disorders; health issues, including breast health, osteoporosis, and menopause; geriatric care ranging from complex medical issues to pain management and palliative care; and musculoskeletal and inflammatory bowel diseases. It also offers interpreter services, chaplaincy and spiritual care, palliative care services, nutrition and food services, and education. Mount Sinai...
Joseph and Wolf Lebovic Health Complex
600 University Avenue
Toronto, ON M5G 1X5
Founded in 1922
Key Executives for Mount Sinai Hospital
Chief Executive Officer of Mount Sinai Medical Center and President of Mount Sinai Medical Center
Chief Nursing Executive and Senior Vice President of Patient Service
Chairman of Department of Cardiothoracic Surgery - Icahn School of Medicine
Treasurer and Vice Chairman of Resources Committee
Compensation as of Fiscal Year 2013.
Mount Sinai Hospital Key Developments
Allan S. Stewart, MD, Joins The Mount Sinai Hospital as Director of Aortic Surgery and Co-Director of the Valve Center in the Department of Cardiothoracic Surgery
Nov 6 13
The Mount Sinai Hospital announced cardiac surgeon, Allan S. Stewart, MD, has been appointed Director of Aortic Surgery and Co-Director of the Valve Center in the Department of Cardiothoracic Surgery. Dr. Stewart joins Mount Sinai from NewYork-Presbyterian Hospital/Columbia University Medical Center.
Mount Sinai Hospital Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
Mount Sinai Hospital Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
Miraculins to License Additional Preeclampsia Technology from Mount Sinai Hospital
Mar 11 13
Miraculins Inc. announced its plans to add to its suite of maternal health biomarkers under license from Mount Sinai Hospital's Samuel Lunenfeld Research Institute by signing a term sheet to license methods and reagents for detecting hydroxylated Hypoxia Inducible Factor 1 alpha, a promising biomarker with potential in differentiating high and low risk pregnancies, including risk of preeclampsia. The technology is part of the pioneering research on preeclampsia and placental development being conducted by Dr. Isabella Caniggia, Senior Investigator at the Samuel Lunenfeld Research Institute, in collaboration with Dr. Martin Post, a Senior Scientist at The Hospital for Sick Children. Dr. Caniggia is also a member of Miraculins' Scientific Advisory Board and is cross-appointed at the University of Toronto as a Professor in Obstetrics and Gynecology as well as Physiology. In addition to its promise in maternal health and preeclampsia, HIF-1aOH also presents an opportunity as a cancer biomarker and of further note, the license will include unique monoclonal antibodies highly sensitive to HIF-1aOH and the exclusive rights to manufacture reagents that measure the biomarker using materials developed by Dr. Caniggia.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|